A laboratorija, MB - financials and debts

Company age: 5 y. 8 mo.

Update

A laboratorija - Company finances

EUR
2021
From: 2021-01-11
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 37,586 45,336 40,599 42,700 51,716
Profit before tax 11,914 6,062 661 -6,352 -3,838
Net profit 11,318 5,753 628 -6,352 -3,838
Equity 11,318 17,071 17,699 11,347 5,789
Liabilities - 4,485 3,435 0 1,244
Non-current assets 470 336 571 336 168
Current assets 15,187 21,220 20,563 15,293 6,865
Total assets 15,657 21,556 21,134 15,629 7,033
Taxes paid
STI taxes - - 337 36 -
Financial indicators
Revenue change y/y - +20.6% -10.4% +5.2% +21.1%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 72.3% 26.7% 3.0% -40.6% -54.6%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 100.0% 33.7% 3.5% -56.0% -66.3%
Profit margin Net profit margin. Shows the overall profitability of the company. 30.1% 12.7% 1.5% -14.9% -7.4%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 31.7% 13.4% 1.6% -14.9% -7.4%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - 0.3 0.2 - 0.2
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

A laboratorija - Social security debts

The amount of overdue SODRA debt for the company A laboratorija as of the last working day is: 80 €

From To Debt, €
2026-09-05 2026-09-14 80.48
2026-09-01 2026-09-02 80.48
2026-08-01 2026-08-11 563.36
2026-07-01 2026-07-31 482.88
2026-06-11 2026-06-30 402.40
2026-01-01 2026-03-31 139.80
2025-12-02 2025-12-31 67.35
2025-10-01 2025-10-31 72.45
2025-09-02 2025-09-30 144.90
2025-08-01 2025-09-01 72.45
2025-07-01 2025-07-31 144.90
2025-06-04 2025-06-30 72.45
2025-06-03 2025-06-03 217.35
2025-05-04 2025-06-02 144.90
2025-04-01 2025-04-30 72.45
2025-03-04 2025-03-31 144.90
2025-03-03 2025-03-03 72.45
2025-03-01 2025-03-02 144.90
2025-02-01 2025-02-28 72.45
2025-01-02 2025-01-31 129.00
2024-12-03 2024-12-31 64.50
2024-11-04 2024-11-30 129.00
2024-10-01 2024-11-03 64.50
2024-09-03 2024-09-30 129.00
2024-08-01 2024-09-02 64.50
2024-07-02 2024-07-31 1811.27
2024-06-03 2024-07-01 1746.77
2024-05-15 2024-06-02 1682.27
2024-05-02 2024-05-14 1458.22
2024-04-03 2024-05-01 1393.72
2024-03-01 2024-04-02 1329.22
2024-02-26 2024-02-29 1264.72
2024-02-01 2024-02-25 1424.27
2024-01-03 2024-01-31 1359.77
2023-12-01 2024-01-02 1301.14
2023-11-03 2023-11-30 1242.51
2023-10-03 2023-11-02 1183.88
2023-09-01 2023-10-02 1125.25
2023-08-09 2023-08-31 1066.62
2023-07-19 2023-07-31 1007.99
2023-01-03 2023-01-31 656.21
2022-12-13 2023-01-02 605.26
2022-01-03 2022-01-31 44.81
2021-11-04 2021-12-31 44.81
2021-10-01 2021-10-31 44.81
2021-09-01 2021-09-30 89.62

A laboratorija - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company A laboratorija is: 0 €

From To Overdue, €
2024-06-28 2026-09-02 0.09

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
A laboratorija, MB (code 305679818) is a Lithuanian small partnership engaged in the manufacture of other medical and dental devices, instruments and supplies. In 2025, the company generated revenue of €51.7K, up 21.1% year on year and 27.4% over two years. Despite the higher turnover, profitability remained negative: net loss was €3.8K, compared with a €6.4K loss in 2024 and a small €628 profit in 2023. The 2025 profit margin was -7.4%, showing an improvement from -14.9% in 2024 but still below break-even. Balance sheet size also contracted over the period, with total assets falling from €21.1K in 2023 to €15.6K in 2024 and €7.0K in 2025. Equity declined from €17.7K to €5.8K, while liabilities were €1.2K in 2025. The equity ratio stood at 82.3%, debt-to-equity at 0.21, and asset turnover at 7.35x, indicating a small, asset-light structure with relatively efficient use of assets in revenue generation.